In a new job - June 19, 2020
Zealand Pharma appoints US President
Zealand Pharma has announced the appointment of Frank Sanders as President of Zealand Pharma U.S. Frank Sanders will join Zealand on July 6, 2020. “I am pleased to welcome Frank Sanders to Zealand Pharma, and am confident that he will provide strong and experienced leadership for our U.S. organization,” said Emmanuel Dulac, President and Chief Executive […]
Agreement - September 4, 2019
Zealand Pharma and Boehringer Ingelheim initiate Phase 2 development of BI 456906
Boehringer Ingelheim plans to initiate Phase 2 development of the GLP-1/glucagon dual agonist BI 456906, which was in-licensed from Zealand. Boehringer Ingelheim and Zealand have a longstanding partnership, bringing together Zealand’s expertise in the discovery of peptide-based medicines with Boehringer Ingelheim’s expertise in the research and development of novel medicines for cardiometabolic diseases. Potential as […]
In a new job - September 2, 2019
Zealand Pharma appoints new CFO and relocates headquarters
The company has announced the relocation into new corporate headquarters located at Sydmarken 11 in Søborg, and the appointment of a new Chief Financial Officer. The move will accommodate Zealand’s continued workforce growth, which has been steadily increasing to support the number of clinical development programs as well as the longer-term strategic initiative for introducing […]
In a new job - August 1, 2019
Zealand Pharma’s CSO leaves the company
The company announces that Andrew Parker will leave his position as Executive Vice President and Chief Scientific Officer. Andrew Parker has accepted a top executive leadership position in a non-competing biotechnology company outside Denmark. “I have thoroughly enjoyed my time at Zealand Pharma, contributing to an exceptional growth story over the last few years and […]
In a new job - April 12, 2019
Zealand Pharma appoints new CEO
Emmanuel Dulac will join Zealand Pharma as new Chief Executive Officer on April 22, 2019. Emmanuel Dulac has 25 years of experience in the pharmaceutical industry, with a strong record of commercial and operational leadership underpinned by several senior roles in Europe and North America, reports the company. Since August 2016, Emmanuel has been the […]
Clinical Trials - March 12, 2019
First patient dosed in Zealand Pharma trial
The company has announced the dosing of the first patient in their first Phase 3 trial to evaluate dasiglucagon as a potential treatment option for children with CHI. “With the first child dosed, this Phase 3 trial takes an important step toward establishing dasiglucagon as a potential treatment of congenital hyperinsulinism,” said Adam Steensberg, Interim CEO […]
